Dermatology

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

Patients with atopic dermatitis treated with camoteskimab saw significant reductions in their mean EASI score at Week 16 compared to placebo.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

This episode highlights the challenges of navigating demanding medical careers while raising young children, with insights and practical strategies.

The label update expands the treatment eligible population to include dystrophic epidermolysis bullosa patients from birth and allows at-home application.

This review highlights several evidence-based approaches to promoting skin longevity and preventing signs of aging.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

Red light photodynamic therapy with 10% ALA gel shows superior clearance rates compared to vehicle treatment.

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

A new position paper established an evidence-based definition for systemic corticosteroid (SCS) duration in individuals with atopic dermatitis.

These data indicate that greater maternal dietary diversity during pregnancy may be linked with a diminished risk of atopic dermatitis during early childhood.

This study compared a recent risk prediction tool for invasive melanoma and its performance compared to existing prediction tools.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Preliminary topline results have been released from the ASCEND study on rocatinlimab in adults and adolescents with atopic dermatitis.

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

Intralesional triamcinolone showed significantly greater hair regrowth and patient satisfaction.

This announcement highlights delgocitinib cream availability for the treatment of US adults living with moderate-to-severe chronic hand eczema, or CHE.

In this observational analysis, investigators highlight the potential causal link identified between NHHR and psoriasis development.

Investigators explored the characteristics of pediatric-onset hidradenitis suppurativa, emphasizing the need for earlier detection to expedite diagnosis.

Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 clinical trial data, in this week's essential news roundup.

NB-UVB phototherapy was highlighted in this study, with positive findings suggesting the treatment is an effective oral cyclosporine alternative.

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

Amlitelimab met its primary and key secondary endpoints in the COAST 1 phase 3 study of adults and adolescents with atopic dermatitis.